Empaglin Tablet 10 mg (Empagliflozin)
Empagliflozin 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.
MFDS item code 202102264 · Approved 2021.03.12
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar in adults with type 2 diabetes. It may also be used alone, but in cases where blood sugar control is insufficient, it can be combined with metformin, pioglitazone, sulfonylureas, or DPP-4 inhibitors to enhance therapeutic effect. In patients with concurrent cardiovascular disease, it should be administered with reference to specialized clinical trial information. This medication effectively improves blood sugar control and aids in diabetes management.
The recommended dose of this medicine is 10 mg once daily for monotherapy and as add-on combination therapy with other glucose-lowering agents, such as insulin. If additional glycemic control is needed and 10 mg of this medicine is well tolerated, the dose may be increased to 25 mg once daily. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3, Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you forget to take this medicine, take it as soon as you remember. Do not take double the dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent eGFR below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. Discontinue this medicine if the eGFR decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in older adults aged 85 years and older due to limited clinical experience (see Precautions for Use, section 4, General Precautions).
This medication should not be used in patients with allergic reactions to the active ingredient or any of the components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. This medication is not to be used in patients with severely impaired kidney function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73 m2 or those with end-stage kidney disease or undergoing dialysis. As this medication contains lactose, it should not be given to patients with genetic issues such as galactose intolerance, lactose deficiency, or glucose-galactose malabsorption. In patients with decreased kidney function, this medication should be given with caution, and it is important to regularly monitor kidney function before and during administration. In patients with mild to moderate heart failure, it should be used cautiously, and it is not recommended for patients with severe heart failure. This medication may increase the risk of hypoglycemia when used in conjunction with insulin or sulfonylureas, so dosage adjustments of the hypoglycemics may be necessary when used together. While taking this medication, side effects such as hypoglycemia, infections, increased urination, urinary tract infections, and decreased fluid volume may occur, and any unusual symptoms should be promptly discussed with healthcare personnel. Especially, even if blood sugar is within the normal range, ketoacidosis may occur; symptoms such as nausea, vomiting, abdominal pain, and breathing difficulties require immediate testing and treatment. Elderly patients aged 75 and older are at greater risk of fluid loss; therefore, caution is required when using this medication, and its use in patients aged 85 and older is not recommended. This medication carries a risk of dehydration or hypotension, so it should be used cautiously in patients with low blood pressure or cardiovascular diseases. There may be an increased risk of urinary infections and genital fungal infections, so prompt treatment is required if symptoms of infection occur. Taking this medication may result in a positive glucose test in urine, which needs to be taken into account. Care should be taken when driving or operating machinery, especially in case of hypoglycemia risk. There may be possible interactions with other medications; inform healthcare professionals of any medications being taken. Women who are pregnant or planning to become pregnant are advised against using this medication, and breastfeeding women should discontinue breastfeeding if taking this medication. The safety and effectiveness of this medication have not been established in children or adolescents. In the case of overdose, no specific toxic symptoms have been reported; however, appropriate treatment based on clinical condition may be necessary. This medication should be stored out of reach of children, and it is safe not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain a storage temperature between 1°C and 30°C.
Pale yellow, biconvex round film-coated tablet
10 tablets/box [(10 tablets/PTP x 1)], 30 tablets/box [(10 tablets/PTP x 3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
Jinyang Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.